HEXADROL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HEXADROL (HEXADROL).
Synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to regulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
| Metabolism | Primarily hepatic via CYP3A4; metabolites are excreted in urine. |
| Excretion | Primarily renal: ~65-80% as unchanged drug and metabolites via glomerular filtration, with tubular reabsorption; minor biliary/fecal (5-10%). |
| Half-life | Terminal elimination half-life: 36-54 hours; prolonged in hepatic impairment (up to 72 hours) due to reduced clearance. |
| Protein binding | 70-80% bound; primary binding to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | 0.8-1.0 L/kg; indicates extensive tissue distribution, including crossing the blood-brain barrier. |
| Bioavailability | Oral: 80-90% (well absorbed); IM: 100% (systemic). |
| Onset of Action | Oral: 1-2 hours; IV: rapid (minutes to 1 hour); IM: 1-2 hours; topical: varies. |
| Duration of Action | Oral: 1-2 days (due to long half-life); IV: 1-2 days; IM: 1-3 weeks (repository forms). |
| Molecular Weight | 392.46 |
Adult: 0.75-9 mg/day orally in divided doses every 6-12 hours; IV/IM: initial 0.5-9 mg/day in divided doses every 6-12 hours.
| Dosage form | ELIXIR |
| Renal impairment | No specific GFR-based dose adjustments required; use with caution in severe renal impairment (eGFR <30 mL/min). |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B/C: reduce dose by 50% or use lowest effective dose. |
| Pediatric use | 0.08-0.3 mg/kg/day or 2.5-10 mg/m²/day orally in divided doses every 6-12 hours; IV/IM: 0.08-0.3 mg/kg/day in divided doses every 12-24 hours. |
| Geriatric use | Start at lowest effective dose (e.g., 0.75 mg/day) and titrate slowly; monitor for hyperglycemia, osteoporosis, and infections. |
| 1st trimester | Use only if clearly needed; may increase risk of cleft palate when used in first trimester. Weigh benefits vs risks. |
| 2nd trimester | May cause fetal adrenal suppression; use only if maternal benefit outweighs fetal risk. |
| 3rd trimester | May cause neonatal adrenal suppression; use only if clearly needed. Monitor neonate for signs of adrenal insufficiency. |
Clinical note
Comprehensive clinical and safety monograph for HEXADROL (HEXADROL).
| Placental transfer | Readily crosses placenta; metabolized by placental 11β-HSD2 but sufficient active drug reaches fetal circulation to cause adrenal suppression with prolonged use. |
| Breastfeeding | Excreted in human milk but not expected to cause adverse effects in nursing infants at maternal doses ≤ 20 mg/day. Use caution with high doses or prolonged therapy. |
■ FDA Black Box Warning
None
| Serious Effects |
Systemic fungal infectionsHypersensitivity to dexamethasone or any componentAdministration of live or live-attenuated vaccines with immunosuppressive doses
| Precautions | Immunosuppression and increased susceptibility to infections, Hypothalamic-pituitary-adrenal axis suppression and adrenal insufficiency with withdrawal, Gastrointestinal perforation (especially in colitis), Osteoporosis and avascular necrosis, Ocular effects: cataracts, glaucoma, Psychiatric disturbances, Cardiovascular effects: hypertension, fluid retention, Growth suppression in children |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase dexamethasone levels. Limit sodium intake to reduce fluid retention. Maintain adequate calcium and vitamin D intake to counteract bone loss. |
Loading safety data…
| Lactation Rating | L2 |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (odds ratio 3.6), orofacial clefts; second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, oligohydramnios with prolonged high-dose use. |
| Fetal Monitoring | Maternal: Blood pressure, blood glucose, signs of infection; Fetal: Ultrasound for growth and amniotic fluid index; neonatal: Adrenal function if prolonged exposure. |
| Fertility Effects | May inhibit gonadotropin secretion leading to ovulatory dysfunction; reversible upon discontinuation. |
| Clinical Pearls | HEXADROL (dexamethasone) has a long duration of action (36-54 hours), allowing for once-daily dosing. Use with caution in patients with diabetes, as it can cause hyperglycemia. For cerebral edema, rapid onset of action is beneficial; high doses may cause psychosis. Do not withdraw abruptly after prolonged use; taper to avoid adrenal insufficiency. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · Report any unusual weight gain, swelling, or changes in vision immediately. · Avoid live vaccines while on this medication. · May cause increased appetite, insomnia, or mood changes; discuss if severe. · Wear a medical alert ID if using long-term. |